Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Other/Metastatic

Metastatic

28

Pipeline Programs↗

17

Active Trials↗

34

Companies Involved↗

Metastatic is an emerging landscape with 28 programs across 34 companies. The most active players are Rottapharm Biotech, Avistone Biotechnology Co., Ltd., Lyvgen Biopharma Holdings Limited. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

54/100

Pipeline Velocity

19/100

Mech. Concentration

19/100

Completion Rate

58/100

Attrition Rate

27/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Rottapharm Biotech

2 programs

Avistone Biotechnology Co., Ltd.

1 program

Lyvgen Biopharma Holdings Limited

1 program

Myeloid Therapeutics

1 program

Pipeline

Programs by Phase

Preclinical2

Luspatercept

Bristol-Myers Squibb

CHG0521 Oral Coating

Guangzhou University of Traditional Chinese Medicine

Phase 19

NVL-330

Nuvalent Inc.

LVGN7409

Lyvgen Biopharma Holdings Limited

MT-303

Myeloid Therapeutics

Tislelizumab

BeiGene

Durvalumab

AstraZeneca

Phase 216

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Cetuximab

Imclone

Vebreltinib

Avistone Biotechnology Co., Ltd.

Dostarlimab

Glaxo Dba Glaxosmithkline

Phase 31

JMKX001899

Jemincare

Approved

No programs

Analysis

Modality Breakdown

27programs

Monoclonal antibody1452%

Small molecule1037%

Antibody–drug conjugate27%

Protein / enzyme14%

Modality classified for 100% of 28 pipeline programs.

Analysis

Trial Status

105

clinical trials

Completed42 · 40%

Terminated26 · 25%

Unknown status14 · 13%

Active, not recruiting7 · 7%

Recruiting7 · 7%

Not yet recruiting3 · 3%

Other6 · 6%

Clinical Trials

Trial Activity

105 trials

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Recruiting·MMyeloid Therapeutics·Phase 1·NCT06478693·70 enrolled

First-line mCapOX+Cetuximab vs. mFOLFOX6+Cetuximab for Metastatic Left-sided CRC With Wild-type RAS/BRAF Genes

Recruiting·WWest China Hospital·Phase 2·NCT05022030·150 enrolled

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT06553885·40 enrolled

PET/CT-Directed Free of Therapy for Metastatic RCC Patients With IMDC Favorable or Intermediate Risk

Recruiting·JJinling Hospital, China·Phase 2·NCT07175480·30 enrolled

Vebreltinib for Advanced or Metastatic CCS

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07153887·30 enrolled

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

Recruiting·NNuvalent Inc.·Phase 1·NCT06521554·200 enrolled

Sacituzumab Govitecan Plus EV in Metastatic UC

Recruiting·—·Phase 1/2·NCT04724018·106 enrolled

Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy

Active, not recruiting·LLyvgen Biopharma Holdings Limited·Phase 1·NCT04635995·126 enrolled

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

Active, not recruiting·UUniversity of Southern California·Phase 1·NCT04387084·10 enrolled

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Active, not recruiting·—·Phase 2·NCT04313504·23 enrolled

Multiomics Approach in Metastatic Clear Renal Cell Carcnoma

Active, not recruiting·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·N/A·NCT05782400·100 enrolled

Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

Active, not recruiting·UUniversity of California, San Diego·Phase 2·NCT03646461·5 enrolled

Radiometabolic Therapy With 177Lu PSMA in PSMA PET/CT Positive Advanced/Metastatic Tumours:

Active, not recruiting·IIstituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS·Phase 2·NCT05867615·83 enrolled

Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers

Active, not recruiting·RRottapharm Biotech·Phase 1/2·NCT05205330·107 enrolled

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Not yet recruiting·JJemincare·Phase 3·NCT07242274·472 enrolled

Page 1 of 7

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)